Novel targets and biomarkers for anti-atherosclerotic therapy

Current Pharmaceutical Design

Volumn 19, Issue 33, 2013, Pages 5837-5839

  Bobryshev, Yuri V ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Anti atherosclerotic therapy; Atherogenesis; Atherosclerosis; Biomarkers; Dendritic cells; Immuneinflammatory cells; Macrophages; T cells; Targets

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN DERIVATIVE; MICRORNA; NATURAL PRODUCT; PHYTOESTROGEN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ANGIOGRAPHY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ATHEROSCLEROSIS; DENDRITIC CELL; DRUG TARGETING; EDITORIAL; HUMAN; IMMUNOTHERAPY; MACROPHAGE; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RISK FACTOR; T LYMPHOCYTE;

ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84884234823     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319330001     Document Type: Editorial

References (14)

1. Roubille F, Kritikou EA, Roubille C, Tardif JC. Emerging anti-inflammatory therapies for atherosclerosis. Curr Pharm Des 2013; 19(33): 5840-9.
2. Ketelhuth DFJ, Gisterå A, Johansson DK, Hansson GK. T cell-based therapies for atherosclerosis. Curr Pharm Des 2013; 19(33): 5850-8.
3. Gratchev A, Ovsiy I, Manousaridis I, Riabov V, Orekhov A, Kzhyshkowska J. Novel monocyte biomarkers of atherogenic conditions. Curr Pharm Des 2013; 19(33): 5859-64.
4. Kruth HS. Fluid-Phase Pinocytosis of LDL by Macrophages: A Novel Target to Reduce Macrophage Cholesterol Accumulation in Atherosclerotic Lesions. Curr Pharm Des 2013; 19(33): 5865-72.
5. Van Brussel I, Schrijvers DM, Van Vré EA, Bult H. Potential Use of Dendritic Cells for Anti-Atherosclerotic Therapy. Curr Pharm Des 2013;?????
6. Cartland S, Jessup W. Dendritic Cells in Atherosclerosis. Curr Pharm Des 2013; 19(33): 5873-82.
7. Zhao J, Zhua H, Wang S, Ma X, Liu X, Wang C, Zhao H, Fan S, Jin X, Wanga K, Zoua Y, Hu K, Sun A, Ge J. Naoxintong Protects against Atherosclerosis through Lipid-lowering and Inhibiting Maturation of Dendritic Cells in LDL Receptor Knockout Mice fed a High-fat Diet. Curr Pharm Des 2013; 19(33): 5891-6.
8. Rosas E, Sobenin I, Orekhov A, Elazer R. Edelman ER, Balcells M. Importance of receptor-targeted systems in the battle against atherosclerosis. Curr Pharm Des 2013; 19(33): 5897-903.
9. Bukrinsky M, Orekhov A, Ditiatkovski M, Sviridov D. Cyclophilins in atherosclerosis: a new therapeutic target. Curr Pharm Des 2013; 19(33): 5904-8.
10. Orekhov AN. Direct Anti-Atherosclerotic Therapy; Development of Natural Anti-Atherosclerotic Drugs Preventing Cellular Cholesterol Retention. Curr Pharm Des 2013; 19(33): 5909-28.
11. Siemelink MA, Pasterkamp G. Taking risk prediction to the next level. Advances in biomarker research for atherosclerosis. Curr Pharm Des 2013; 19(33): 5929-41.
12. Sobenin IA, Chistiakov DA, Bobryshev YV, Postnov AY, Orekhov AN. Mitochondrial Mutations in Atherosclerosis: New Solutions in Research and Possible Clinical Applications. Curr Pharm Des 2013; 19(33): 5942-53.
13. Sobenin IA, Chistiakov DA, Bobryshev YV, Orekhov AN. Blood Atherogenicity as a Target for Antiatherosclerotic Therapy. Curr Pharm Des 2013; 19(33): 5954-62.
14. Puri R, Nissen SE. The Complementary Roles of Imaging and 'Omics' for Future Anti-atherosclerotic Drug Development. Curr Pharm Des 2013; 19(33): 5963-71.